July 20, 2015
As with our recent national recognition from ASCO (American Society of Clinical Oncology) for clinical trials research excellence, we’re again proud to announce another major accomplishment in our quest to provide OHC patients with the most advanced research and cancer care treatments.
We’d like to share with you the news release below that we’ve sent to major media outlets throughout the country. You may have noticed the article in a recent issue of The Cincinnati Enquirer:
OHC FEATURED IN THE NEW ENGLAND JOURNAL OF MEDICINE FOR CLINICAL TRIAL THAT LED TO A NEW FDA-APPROVED DRUG FOR LUNG CANCER
CINCINNATI – OHC, the region’s premier provider of treatments for adult cancer and complex blood disorders, is featured in the June issue of the New England Journal of Medicine for one of the largest clinical trial enrollments for a new FDA-approved drug to fight lung cancer, anti–PD-1 agent Nivolumab (Opdivo). The drug was approved three months ahead of the FDA’s scheduled decision date.
“Thank you to our physicians, research staff and clinical staff for a tremendous effort to serve our patients during this clinical trial,” said Dr. Waterhouse, OHC’s Research Program Medical Director. “We are proud of the difference we are making in the lives of our patients and excited to be recognized in such a prestigious publication.”
The New England Journal of Medicine article details how this randomized, open-label, international, phase III study evaluated the efficacy and safety of Nivolumab compared to Docetaxel in the treatment of patients with advanced squamous-cell non-small-cell lung cancer (NSCLC).
The FDA approved Nivolumab because of the responses that the clinical trail enrollees had to the drug. J.P. Heiremans, an OHC patient and participant in the clinical trial, remains on the drug today. His experience at OHC has inspired him to become a volunteer in the clinic several times a week where he spends time with patients, comforting them where he can, and sharing parts of his own experience along the way.
“While its an honor to have the results of this study featured in the New England Journal of Medicine, what matters most is the results we are seeing from Nivolumab with patients like J.D.,” said Dr. Waterhouse. “We are giving them hope and courage to fight cancer and that’s our mission.”
Bristol Myers Squibb (BMS), the manufacturer of Nivolumab is working on a timetable for publication and presentation of the study data. The approval for the new drug is based on data from the phase III CheckMate-017 trial in which Nivolumab improved overall survival (OS) by 3.2 months versus Docetaxel in previously treated patients with advanced squamous-cell non-small-cell lung cancer (NSCLC).
The OHC Research Program currently participates in many early drug development research trials, which provides innovative, cutting edge options for patients. OHC was recently recognized as one of six community oncology programs in the country by the Conquer Cancer Foundation for the American Society of Clinical Oncology (ASCO) for its commitment to high-quality clinical trial programs.
For more than 30 years, OHC has served as the region’s premier provider of treatments for adult cancer and complex blood disorders, offering a wide range of services, state-of-the-art treatments and technologies. OHC puts patients first by delivering leading-edge, compassionate, and convenient care, tailored to meet a patient’s medical and personal needs.
With more than 70 physicians and advanced practice providers, OHC treats nearly every form of adult cancer and complex blood disorders with medical, radiation and gynecologic oncology specialists. OHC offers clinical research trials in cutting-edge protocols and the most experienced adult blood and marrow transplant center in Cincinnati. With neighborhood locations throughout the tri-state area, OHC is one of the largest independent oncology practices in the United States.Comments (0)